Key result
Clonal hematopoiesis of indeterminate potential (CHIP) was associated with a significantly higher risk of major adverse cardiovascular events in patients with STEMI (HR 2.23).
Why the study?
The study was conducted to elucidate the extent and clinical implications of CHIP prevalence in STEMI patients and evaluate its utility for risk stratification in long-term outcomes.
Does the presence of clonal hematopoiesis of indeterminate potential (CHIP) increase the risk of major adverse cardiovascular events in patients with STEMI?
Cohort (n=807)
No
Does the presence of clonal hematopoiesis of indeterminate potential (CHIP) increase the risk of major adverse cardiovascular events in patients with STEMI?
Hazard Ratio: 2.23 (95% CI 1.16–4.28)
p-value: p=0.015
The presence of CHIP mutations, particularly in ASXL1 and CREBBP, is prevalent in STEMI patients and significantly increases the long-term risk of major adverse cardiovascular events.
No takes yet. Share an insight, caveat, or question.
CHIP was associated with higher post-STEMI MACE risk; hypothesis-generating for risk stratification and requires prospective validation.
Fan et al. (2025) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=807). Clonal hematopoiesis of indeterminate potential (CHIP) vs. No CHIP (non-carriers) was evaluated on Major adverse cardiovascular events (MACE) (HR 2.23, 95% CI 1.16-4.28, p=0.015). Clonal hematopoiesis of indeterminate potential (CHIP) was associated with a significantly higher risk of major adverse cardiovascular events in patients with STEMI (HR 2.23).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: